Valuation: Tonix Pharmaceuticals Holding Corp.

Market Cap 217M 186M 174M 160M 300M 20.75B 305M 2.05B 804M 10.41B 815M 798M 34.41B P/E 2026 *
-1.3x
P/E 2027 * -2.06x
Enterprise Value 217M 186M 174M 160M 300M 20.75B 305M 2.05B 804M 10.41B 815M 798M 34.41B EV / Sales 2026 *
3.87x
EV / Sales 2027 * 1.87x
Free-Float
99.87%
Yield 2026 *
-
Yield 2027 * -
08-18 Tonix Pharmaceuticals Holding Corp. Announces Appointment of Seth Lederman as Interim Chief Medical Officer CI
08-10 Tonix Pharmaceuticals Holding Corp., Q2 2026 Earnings Call, Aug 10, 2026
08-10 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-03 Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US CI
07-21 Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026 CI
07-15 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
07-13 Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage CI
07-13 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT
06-29 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT
06-29 Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder CI
06-25 Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT MT
06-08 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
06-08 Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA CI
1 week+6.06%
Current month+26.83%
1 month+15.62%
3 months-7.40%
6 months-17.02%
Current year-18.72%
1 week 11.79
Extreme 11.79
13.16
1 month 9.4
Extreme 9.4
13.89
Current year 9.4
Extreme 9.4
19.95
1 year 9.4
Extreme 9.4
39.45
3 years 6.76
Extreme 6.76
3,232
5 years 6.76
Extreme 6.76
497,792
10 years 6.76
Extreme 6.76
1,750,000,000
Manager TitleAgeSince
Chief Executive Officer 68 2007-11-15
Director of Finance/CFO 52 2016-01-31
Chief Tech/Sci/R&D Officer 57 2025-02-03
Director TitleAgeSince
Chairman 68 2011-09-30
Director/Board Member 66 2017-09-11
Director/Board Member 81 2018-09-04
Date Insider Type Main position Quantity % Market Cap.
6/30/26 Others

Chief Financial Officer

1,453 0.0123%
3/31/26 Buy

Chief Executive Officer

5,000 0.0425%
2/24/26 Free

Chief Operating Officer

78,023 0.6625%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+6.06%-65.25%-99.58% 217M
+4.29%+4.44%+81.24%+131.70% 1,093B
+1.12%+4.92%+53.93%+63.54% 653B
+2.54%+6.44%+28.42%+76.34% 458B
+1.80%+0.52%+41.20%+44.48% 355B
+1.24%+2.35%+25.99%+41.24% 294B
+2.07%+2.97%+2.27%+12.89% 248B
+3.76%+5.93%+49.17%+69.11% 230B
+1.05%-0.02%-13.96%-52.51% 203B
+3.22%+8.82%+25.32%+94.70% 178B
Average +2.09%+1.34%+22.83%+38.19% 371.07B
Weighted average by Cap. +2.62%+1.45%+46.56%+73.70%

Financials

2026 *2027 *
Net sales 56.04M 48.07M 44.89M 41.18M 77.44M 5.36B 78.72M 530M 207M 2.69B 210M 206M 8.88B 116M 99.62M 93.03M 85.35M 160M 11.1B 163M 1.1B 430M 5.57B 436M 427M 18.41B
Net income -168M -144M -134M -123M -232M -16.05B -236M -1.59B -621M -8.05B -630M -617M -26.61B -153M -131M -122M -112M -211M -14.61B -215M -1.44B -566M -7.33B -574M -561M -24.22B
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
142
Date Price Change Volume
26-08-19 US$12.70 +0.32% 434,010
26-08-18 US$12.66 0.00% 188,428
26-08-17 US$12.66 -0.39% 388,990
26-08-14 US$12.71 +1.68% 348,034
26-08-13 US$12.50 +4.43% 557,778
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
12.66USD
Average target price
42.40USD
Spread / Average Target
+234.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TNXP Stock